Cargando…

Impact of the TNM staging system for thymoma

BACKGROUND: Masaoka-Koga staging system remains the most frequently applied clinical staging system for thymic malignancy. However, the International Association for the Study of Lung Cancer (IASLC)/International Thymic Malignancy Interest Group (ITMIG) proposed a tumor-node-metastasis (TNM) staging...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Alex, Cavalli, Camilla, Harling, Leanne, Harrison-Phipps, Karen, Routledge, Tom, Pilling, John, King, Juliet, Bille, Andrea, Nonaka, Daisuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801005/
https://www.ncbi.nlm.nih.gov/pubmed/35118337
http://dx.doi.org/10.21037/med-21-24
_version_ 1784642349958168576
author Smith, Alex
Cavalli, Camilla
Harling, Leanne
Harrison-Phipps, Karen
Routledge, Tom
Pilling, John
King, Juliet
Bille, Andrea
Nonaka, Daisuke
author_facet Smith, Alex
Cavalli, Camilla
Harling, Leanne
Harrison-Phipps, Karen
Routledge, Tom
Pilling, John
King, Juliet
Bille, Andrea
Nonaka, Daisuke
author_sort Smith, Alex
collection PubMed
description BACKGROUND: Masaoka-Koga staging system remains the most frequently applied clinical staging system for thymic malignancy. However, the International Association for the Study of Lung Cancer (IASLC)/International Thymic Malignancy Interest Group (ITMIG) proposed a tumor-node-metastasis (TNM) staging system in 2014. This study aims to evaluate its impact on stage distribution, clinical implementation, and prognosis for thymomas. METHODS: We performed a single institution, retrospective analysis of 245 consecutive patients who underwent surgical resection for thymoma. 9 patients with thymic carcinoma were excluded. No patients were lost to follow up. Kaplan-Meier survival analysis was used to calculate overall survival. RESULTS: Median age was 62 years; 129 patients (53%) were female. The median overall survival was 158 months (range, 108–208 months), and disease-free survival 194 months (range, 170–218 months). At the end of follow up 63 patients were dead. Early Masaoka-Koga stages I (n=74) and II (n=129) shifted to the IASLC/ITMIG stage I (n=203). 8 patients were down staged from Masaoka-Koga stage III to IASLC/ITMIG stage II because of pericardial involvement. Advanced stages III (Masaoka-Koga: n=30; IASLC/ITMIG: n=22) and IV (Masaoka-Koga: n=12; IASLC/ITMIG: n=12) remained similar and were associated with more aggressive WHO thymoma histotypes (B2/B3). Masaoka-Koga (P=0.004), IASLC/ITMIG staging (P<0.0001) and complete surgical resection (P<0.0001) were statistically associated with survival. At multivariate analysis only R status was an independent prognostic factor for survival. CONCLUSIONS: The proportion of patients with stage I disease increased significantly when IASLC/ITMIG system used, whilst the proportion with stages III and IV were similar in both systems. Completeness of resection, Masaoka-Koga and the IASLC/ITMIG staging system are strong predictors of survival. The TNM staging system is useful in disease management and a strong predictor of overall survival.
format Online
Article
Text
id pubmed-8801005
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-88010052022-02-02 Impact of the TNM staging system for thymoma Smith, Alex Cavalli, Camilla Harling, Leanne Harrison-Phipps, Karen Routledge, Tom Pilling, John King, Juliet Bille, Andrea Nonaka, Daisuke Mediastinum Original Article BACKGROUND: Masaoka-Koga staging system remains the most frequently applied clinical staging system for thymic malignancy. However, the International Association for the Study of Lung Cancer (IASLC)/International Thymic Malignancy Interest Group (ITMIG) proposed a tumor-node-metastasis (TNM) staging system in 2014. This study aims to evaluate its impact on stage distribution, clinical implementation, and prognosis for thymomas. METHODS: We performed a single institution, retrospective analysis of 245 consecutive patients who underwent surgical resection for thymoma. 9 patients with thymic carcinoma were excluded. No patients were lost to follow up. Kaplan-Meier survival analysis was used to calculate overall survival. RESULTS: Median age was 62 years; 129 patients (53%) were female. The median overall survival was 158 months (range, 108–208 months), and disease-free survival 194 months (range, 170–218 months). At the end of follow up 63 patients were dead. Early Masaoka-Koga stages I (n=74) and II (n=129) shifted to the IASLC/ITMIG stage I (n=203). 8 patients were down staged from Masaoka-Koga stage III to IASLC/ITMIG stage II because of pericardial involvement. Advanced stages III (Masaoka-Koga: n=30; IASLC/ITMIG: n=22) and IV (Masaoka-Koga: n=12; IASLC/ITMIG: n=12) remained similar and were associated with more aggressive WHO thymoma histotypes (B2/B3). Masaoka-Koga (P=0.004), IASLC/ITMIG staging (P<0.0001) and complete surgical resection (P<0.0001) were statistically associated with survival. At multivariate analysis only R status was an independent prognostic factor for survival. CONCLUSIONS: The proportion of patients with stage I disease increased significantly when IASLC/ITMIG system used, whilst the proportion with stages III and IV were similar in both systems. Completeness of resection, Masaoka-Koga and the IASLC/ITMIG staging system are strong predictors of survival. The TNM staging system is useful in disease management and a strong predictor of overall survival. AME Publishing Company 2021-12-25 /pmc/articles/PMC8801005/ /pubmed/35118337 http://dx.doi.org/10.21037/med-21-24 Text en 2021 Mediastinum. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
spellingShingle Original Article
Smith, Alex
Cavalli, Camilla
Harling, Leanne
Harrison-Phipps, Karen
Routledge, Tom
Pilling, John
King, Juliet
Bille, Andrea
Nonaka, Daisuke
Impact of the TNM staging system for thymoma
title Impact of the TNM staging system for thymoma
title_full Impact of the TNM staging system for thymoma
title_fullStr Impact of the TNM staging system for thymoma
title_full_unstemmed Impact of the TNM staging system for thymoma
title_short Impact of the TNM staging system for thymoma
title_sort impact of the tnm staging system for thymoma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801005/
https://www.ncbi.nlm.nih.gov/pubmed/35118337
http://dx.doi.org/10.21037/med-21-24
work_keys_str_mv AT smithalex impactofthetnmstagingsystemforthymoma
AT cavallicamilla impactofthetnmstagingsystemforthymoma
AT harlingleanne impactofthetnmstagingsystemforthymoma
AT harrisonphippskaren impactofthetnmstagingsystemforthymoma
AT routledgetom impactofthetnmstagingsystemforthymoma
AT pillingjohn impactofthetnmstagingsystemforthymoma
AT kingjuliet impactofthetnmstagingsystemforthymoma
AT billeandrea impactofthetnmstagingsystemforthymoma
AT nonakadaisuke impactofthetnmstagingsystemforthymoma